El interés en corto de Amer Sports da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Amer Sports. Los datos de interés en corto se actualizan cada dos semanas.

Amer Sports (NYSE:AS) Bolsa, Informe de interés en corto

Amer Sports

Amer Sports manages a diverse portfolio of 10 outdoor and action sports brands that collectively generated revenue of $4.4 billion in 2023. Although primarily owned by the Chinese conglomerate Anta Sports, Amer operates with a degree of autonomy. In its rapidly expanding China business, the company is subject to closer oversight, but it manages its operations outside of China with relative independence. In 2023, the firm generates 40% of its revenue from the Americas, 33% from Europe, the Middle East, and Africa, 19% from China, and 7% from Asia-Pacific, excluding China.

Amer Sports Inc

ASA Gold And Precious Metals Ltd

AT & S AUSTRIA TECH & SYS by AT&S Austria Technologie & SystemTechnik AG Leoben

AT&S Austria Technologie & Systemtechnik AG

AUSTRALIAN AGRICULTURAL by Australian Agricultural Co Ltd.

Australian Agricultural Co Ltd

Sendas Distribuidora SA ADR (Sponsored)

SENDAS DISTRIBUDRA S/ADR by Sendas Distribuidora S.A.

Sendas Distribuidora SA

American Salars Lithium Inc

ASSURANCEAMERICA by AssuranceAmerica Corp.

Asana Inc

Waitr Holdings Inc

Aurora Spine Corp

WAITR HOLDINGS INC by Waitr Holdings Inc.

ASIA STANDARD INTL GP ORD by Asia Standard International Group Ltd.

Asia Standard International Group Ltd

ASI AVIATION INC by Asi Aviation Inc.

Assa Abloy AB

Associated Banc-Corp

Associated Banc-Corp 6.625% Fixed-Rate Reset Subordinated Notes due 2033

ASSOCIATED BRIT FOOD ORD by Associated British Foods plc

Associated British Foods PLC

ASSOCIATED BRI/F UNSP/ADR by Associated British Foods plc

ASAHI GROUP HLDGS U/ADR by Asahi Group Holdings Ltd.

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Holdings Inc

Aspire Biopharma Holdings, Inc. - Warrant

ASAHI GROUP HOLDINGS ORD by Asahi Group Holdings Ltd.

Asahi Group Holdings Ltd

Associated Banc-Corp Depositary Shares, each representing a 1/40th interest in a share of 5.875% Non-Cumulative Perpetual Preferred Stock, Series E

Associated Banc-Corp Depositary Shares, each representing a 1/40th interest in a share of Associated Banc-Corp 5.625% Non-Cumulative Perpetual Preferred Stock, Series F

Ardmore Shipping Corporation Common Stock

Ardmore Shipping Corp

A SPAC I ACQUISITION CORP USD CL A ORD SHS

A SPAC I ACQUISITION CORP USD RTS

A SPAC I ACQUISITION CORP USD UNITS CONSISTING ONE CL A ORD SH OF NO PAR VALUE & ONE

A SPAC I ACQUISITION CORP WT EXP

A SPAC II ACQUISITION CORP CL A

A SPAC II ACQ CORP by A SPAC II Acquisition Corp.

A SPAC II Acquisition Corp

ASCENDIA BRANDS INC by Ascendia Brands, Inc.

A SPAC II ACQUISITION CORP RT

A SPAC II ACQUISITION CORP UNIT 1 CL A& 1/2 WT EXP & 1 RT

A SPAC II ACQUISITION CORP WT EXP

ARISTOCRAT GRP CORP by Aristocrat Group Corp

Aristocrat Group Corp

ASICS Corp

ACOTEC SCIENTIFIC HLD ORD by ACOTEC SCIENTIFIC HLDGS LTD

Acotec Scientific Holdings Ltd

AMSC ASA

Auscrete Corp

ASCLETIS PHARMA INC by Ascletis Pharma Inc.

Ascletis Pharma Inc

Absecon Bancorp

ASCOPIAVE SPA TREVISO ORD by Ascopiave SPA Treviso

Ascopiave SpA

AMER CRYSTAL SUGAR PFD by American Crystal Sugar Co.

American Crystal Sugar Co

ARIZONA SONORAN COPPER CO by Arizona Sonoran Copper Company Inc.

Arizona Sonoran Copper Co Inc

A SPAC II Acquisition Corp Warrants (15/10/2026)

Astro Aerospace Ltd

ASCENDANT RES INC ORD by Ascendant Resources Inc.

Ascendant Resources Inc

ARCTIC STAR EXPL CORP by Arctic Star Exploration Corp.

Arctic Star Exploration Corp

Global X FTSE Southeast Asia ETF

APT SATELLITE HOLDINGS by APT Satellite Holdings Ltd.

APT Satellite Holdings Ltd

AISIN SEIKI CO LTD ORD by Aisin Corporation

Aisin Corp

FlexShares Real Assets Allocation Index Fund

ASIAFIN HLDGS CORP by ASIAFIN HOLDINGS CORP.

Asiafin Holdings Corp

ASFG INC by ASFG, Inc.

APPSOFT TECHNOLOGIES INC by AppSoft Technologies, Inc.

AppSoft Technologies Inc

AMERICAN SCIENTFC RES by American Scientific Resources, Inc.

American Scientific Resources Inc

Associates First Capital Corp

Liberty All Star Growth Fund Inc

abrdn Global Infrastructure Income Fund Common Shares of Beneficial Interest

abrdn Global Infrastructure Income Fund

AGC Inc

ASGN Inc

Asante Gold Corp

ASTRALIS A/S by Astralis A/S

Altri SGPS SA

Altus Group Ltd

ASIA GLOBAL CROSSING A by Asia Global Crossing Ltd.

Asia Global Crossing Ltd

Ashland Inc

Ashtrom Group Ltd

ASBERRY 22 HLDGS INC by ASBERRY 22 HLDGS INC.

Asberry 22 Holdings Inc

ASHLEY SVCS GROUP LTD by ASHLEY SVCS GROUP LTD.

Ashley Services Group Ltd

Xtrackers Harvest CSI 300 China A-Shares ETF

Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF

Ashtead Group PLC

ASHTED GRP PLC UNSP/ADR by Ashtead Group PLC

DBX ETF Trust Xtrackers MSCI China A Inclusion Equity ETF

PROGRESSIVE PLANET NEW by Progressive Planet Solutions Inc.

Progressive Planet Solutions Inc

Matthews International Funds Matthews Pacific Tiger Active ETF

Ategrity Specialty Holdings LLC

ACCREDITED SOLUTIONS INC by Accredited Solutions Inc.

Accredited Solutions Inc

AdvanSix Inc

Permission Coin

ALASKA PACIFIC ENERGY by Alaska Pacific Energy Corp.

Alaska Pacific Energy Corp

ASTIKA HOLDINGS INC by Astika Holdings, Inc.

Astika Holdings Inc

ASKUL Corp

ASKA PHARM HLDGS CO LTD by ASKA PHARMACEUTICAL HLDGS CO LTD

ASKA Pharmaceutical Holdings Co Ltd

AerSale Corp

ASL MARINE HLDGS LTD by ASL Marine Holdings Ltd.

ASL Marine Holdings Ltd

ABRDN EUROPEAN LOGISTICS by ABRDN EUROPEAN LOGISTICS INCOME PLC

Goldman Sachs analyst Duffy Fischer maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Sell and raises the price target from $53 to $59.

News

Price Target

Analyst Ratings

Goldman Sachs Maintains Sell on Nutrien, Raises Price Target to $59

On Thursday, U.S. Food and Drug Administration (FDA) Commissioner Martin A. Makary announced an aggressive timeline to scale the use of <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">artificial intelligence (AI)</a> internally across all FDA centers by June 30, following the completion of a new generative AI pilot for scientific reviewers.
Makary has <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-completion-first-ai-assisted-scientific-review-pilot-and-aggressive-agency-wide-ai" rel="noreferrer noopener">directed</a> all FDA centers to begin deployment immediately, with the goal of full integration by the end of June. Work will continue to expand use cases, improve functionality, and adapt to the evolving needs of each center after June 30.
By that date, all centers will be operating on a common, secure generative AI system integrated with the FDA&#8217;s internal data platforms.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44087329/microsoft-unveils-ai-powered-dragon-copilot-to-ease-clinician-workloads" rel="noreferrer noopener">Microsoft Unveils AI-Powered Dragon Copilot To Ease Clinician Workloads</a>
Makary spoke about the need to shorten the length of the drug approval process and the use of artificial intelligence, among other topics, during the AHA Annual Membership Meeting on Tuesday.
&#8220;We at the FDA now have to ask big questions that we&#8217;ve never asked before,&#8221; Makary <a target="_blank" href="https://www.aha.org/news/headline/2025-05-06-fda-commissioner-talks-shortening-drug-approval-process-benefits-ai" rel="noreferrer noopener">said</a>. &#8220;Why does it take over 10 years for a new drug to come to market? Why are we not modernized with AI and other things?&#8221;
Makary was also optimistic about AI helping to approve new treatments for conditions such as diabetes and certain types of cancer.
According to a media report on Wednesday, OpenAI, which is backed by Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), met with FDA officials to discuss the agency&#8217;s use of AI to speed up drug evaluations.
Makary didn&#8217;t say OpenAI was involved in the project, but sources familiar with it say a small team from OpenAI has met several times in recent weeks with the FDA and two associates from Elon Musk&#8217;s Department of Government Efficiency (DOGE).
They&#8217;ve been discussing a <a target="_blank" href="https://www.wired.com/story/openai-fda-doge-ai-drug-evaluation/" rel="noreferrer noopener">project</a> called &#8220;cderGPT,&#8221; likely referring to the FDA&#8217;s Center for Drug Evaluation and Research (CDER), which regulates over-the-counter and prescription drugs in the U.S., and &#8220;Research GPT.&#8221; Jeremy Walsh, the FDA&#8217;s newly appointed AI officer, has led the talks. No contract has been finalized yet.
According to the May 2024 McKinsey Global Institute report, AI technology could generate&nbsp;$60 billion—$110 billion annually in economic value for the pharmaceutical industry, as it can help speed up the process of identifying compounds, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38768537/from-hype-to-reality-ai-reshapes-pharmaceutical-industry-across-drug-discovery-to-marketing-stock" rel="noreferrer noopener">their development, and approval</a>.
In May 2024, Researchers at&nbsp;Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)&nbsp;Google DeepMind developed AlphaFold 3, a new <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38711266/google-deepmind-develops-latest-ai-model-to-aid-scientists-in-fighting-disease" rel="noreferrer noopener">artificial intelligence (AI) model</a>.
AlphaFold 3 can predict the structure and interactions of biological molecules. This includes proteins, DNA, and RNA, and small molecules that could function as drugs.&nbsp;
Google DeepMind will make the model available for non-commercial use through&nbsp;the AlphaFold server.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45324296/trump-cut-11-billion-in-local-government-fight-back" target="_blank" rel="noreferrer noopener">Trump Admin Cuts $11 Billion In Health Funds — Local Governments Fight Back</a></li>
</ul>
Photo by Tada Images via Shutterstock

GOOG

GOOGL

MSFT

Trump Appointed Martin Makary Targets Faster Drug Approvals With FDA Artificial Intelligence Overhaul

Goldman Sachs analyst Will Nance maintains NCR Voyix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VYX#NYSE">VYX</a>) with a Neutral and raises the price target from $8.5 to $11.

Goldman Sachs Maintains Neutral on NCR Voyix, Raises Price Target to $11

Goldman Sachs analyst Kate McShane maintains National Vision Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) with a Neutral and raises the price target from $13 to $17.

Goldman Sachs Maintains Neutral on National Vision Holdings, Raises Price Target to $17

Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.
Analysts estimate that Aquestive Therapeutics will report an earnings per share (EPS) of $-0.16. 
Aquestive Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.06, which was followed by a 7.53% drop in the share price the next day.
Here's a look at Aquestive Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.13</td>
<td>-0.13</td>
<td>-0.12</td>
<td>-0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.19</td>
<td>-0.13</td>
<td>-0.03</td>
<td>-0.17</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>-8.0%</td>
<td>1.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746814019_0.png" alt="eps graph" />
<h3>Aquestive Therapeutics Share Price Analysis</h3>
Shares of Aquestive Therapeutics were trading at $2.76 as of May 08. Over the last 52-week period, shares are down 14.83%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AQST/earnings">To track all earnings releases for Aquestive Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

AQST

Uncovering Potential: Aquestive Therapeutics's Earnings Preview

Goldman Sachs analyst Lizzie Dove maintains Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) with a Sell and raises the price target from $48 to $55.

Goldman Sachs Maintains Sell on Marriott Vacations, Raises Price Target to $55

United Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBCP#NASDAQ">UBCP</a>) reported quarterly earnings of $0.32 per share. This is a 8.57 percent decrease over earnings of $0.35 per share from the same period last year. The company reported $7.53 million in sales this quarter. This is a 7.84 percent increase over sales of $6.98 million the same period last year.

UBCP

United Bancorp Q1 EPS $0.32 Down From $0.35 YoY, Sales $7.53M Up From $6.98M YoY

In March, the U.S. Department of Health and Human Services (HHS) unveiled a sweeping restructuring plan to cut costs, streamline <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">operations, and refocus priorities</a>.
Congress has long considered HHS vital to national well-being, appropriating $2.5 trillion for Fiscal Year 2024 to support its broad mandate across medicine, public health and social services.
The changes, aligned with President Donald Trump's executive order on government efficiency, will reduce the agency&#8217;s workforce, consolidate divisions and emphasize efforts to <a href="https://www.benzinga.com/government/regulations/25/03/44519638/us-department-of-health-and-human-services-aligns-with-trumps-executive-order-to-cut-10k-jobs-save-18-billion" target="_blank" rel="noreferrer noopener">combat chronic illness</a>.
The&nbsp;restructuring&nbsp;will reduce the HHS workforce by 10,000 full-time employees, leading to annual savings of $1.8 billion.
<ul class="wp-block-list">
<li>Through early retirements and other initiatives, the total number of employees will shrink from 82,000 to 62,000.</li>
</ul>
Multiple states have <a target="_blank" href="https://www.njoag.gov/wp-content/uploads/2025/05/2025-0505_State-of-New-York-v.-Kennedy-Jr.pdf" rel="noreferrer noopener">filed</a> legal challenges to Secretary Robert F. Kennedy Jr.&#8217;s reorganization, arguing that the moves violate constitutional mandates and congressional intent.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43038618/hhs-challenges-vertex-over-fertility-services-program-tied-to-casgevy-gene-therapy" rel="noreferrer noopener">HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is &#8216;Grasping at Straws&#8217;</a>
The states claim the administration's efforts have dismantled the agency in defiance of established laws, severely disrupting health programs critical to Americans nationwide.
In a lawsuit filed on Monday, the states said the sudden layoffs brought HHS operations to a near standstill.
Laboratories stopped testing for infectious diseases, FDA vaccine reviews were missed and vital programs such as Head Start and the Low-Income Home Energy Assistance Program were left unsupported.
The World Trade Center Health Program could no longer certify illnesses and maternal health initiatives were shut down. Meanwhile, grantees and state partners were left without contacts or guidance as key portals and support channels went dark.
Although the terminations affected many employees, the cuts disproportionately targeted specific agencies, including the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Administration for Children and Families (ACF), and the Administration for Community Living (ACL).
20,000 positions—almost a quarter of the HHS workforce—are slated for elimination. Despite the scale, Kennedy reportedly acknowledged that up to 20% of the layoffs were known to be mistakes even before execution.
Kennedy admitted that the decision to forgo a detailed review was driven by a desire to preserve "political momentum."
Importantly, the downsizing was not necessitated by budget constraints—congressional funding has remained stable or increased.
States argue the move was a deliberate effort to sideline the department's role, defying the very laws and mandates that created and funded it. The chaotic restructuring has left the remaining staff unable to process grants, issue funds, review policies, or manage public health emergencies.
In response, Plaintiff States are pursuing declaratory and injunctive relief to halt what they describe as the unlawful dismantling of one of the federal government's most complex and essential departments.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45297979/whats-going-on-with-us-foods-stock-on-thursday" target="_blank" rel="noreferrer noopener">US Foods Dishes Out 40% Net Income Gain, Readies $1 Billion Buyback</a></li>
</ul>
Photo: Shutterstock

Government

Health Care

Politics

Legal

General

Trump's HHS Overhaul Faces Legal Blowback From States Over Deep Staffing Cuts, Slashed Health Programs

Goldman Sachs analyst Michael Ng maintains Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy and lowers the price target from $29 to $25.

INGM

Goldman Sachs Maintains Buy on Ingram Micro Holding, Lowers Price Target to $25

Telsey Advisory Group analyst Dana Telsey reiterated the Outperform rating on Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) <a target="_blank" href="https://www.benzinga.com/quote/BIRK/analyst-ratings" rel="noreferrer noopener">with a price forecast of $70</a>.
The company is set to report its second-quarter results on May 15, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/ac44808411/birkenstock-announces-fiscal-second-quarter-2025-ended-march-31-2025-results-date-and-conference-" rel="noreferrer noopener">before the market opens.</a>
Telsey projects total revenue to grow 17.7% year-over-year to 566.4 million euros, slightly trailing the consensus estimate of 568.2 million euros.
The analyst sees a 30-basis-point expansion in gross margin to 56.6%, narrowly topping the consensus forecast of 56.5%, which implies a 20-basis-point improvement.
Also Read: <a target="_blank" href="http://benzinga.com/25/03/44360179/birkenstock-eyes-rapid-growth-targeting-us-and-global-retail-markets-says-analyst" rel="noreferrer noopener">Birkenstock's US Expansion Has Significant Upside With Fewer Than 10 Stores Today, Analyst Says</a>
Additionally, Telsey analyst pointed out that Birkenstock holds a relative advantage in terms of tariff exposure, as the company manufactures in Germany and only derives 52% of its fiscal 2024 revenue from the Americas, limiting its vulnerability compared to peers in the footwear industry.
The analyst also anticipates that operating expenses will remain flat year-over-year at 27.6%, which is slightly below the consensus figure of 27.7%, reflecting a minor 10-basis-point deleverage.
In aggregate, Telsey forecasts a 180-basis-point improvement in pretax profit margin to 24.8%, which comes in just under the Street's expectation of a 230-basis-point rise to 25.3%.
For the fiscal second quarter, Telsey maintains an adjusted EBITDA estimate of 193.3 million euros, up from 162.3 million euros in the prior-year quarter and closely aligned with the consensus view of €192.9 million.
This projection corresponds to an adjusted EBITDA margin of 34.1%.
Telsey noted that the brand is maintaining strong demand across multiple regions and distribution channels, continuing to execute well despite ongoing global macroeconomic challenges.
The analyst also highlighted the firm's successful efforts in expanding its closed-toe shoe segment across different markets while also driving average selling price growth.
As consumers become more selective with their spending, Telsey sees Birkenstock as a brand well-positioned to thrive due to its premium lifestyle appeal and distinct focus on comfort, a value proposition that's difficult for competitors to replicate.
Price Action: BIRK shares are trading lower by 0.36% to $52.28 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44800974/consumers-go-discount-as-tariff-pressures-mount-warns-analyst" target="_blank" rel="noreferrer noopener">Consumers Go Discount As Tariff Pressures Mount, Warns Analyst</a></li>
</ul>
Photo by Josh Forden via Shutterstock

Analyst Color

Equities

Reiteration

Markets

Trading Ideas

BIRK

Birkenstock Has A Tariff Advantage Going In Q2: Analyst

Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) is preparing to release its quarterly earnings on Monday, 2025-05-12. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Blade Air Mobility to report an earnings per share (EPS) of $-0.10.
The market awaits Blade Air Mobility's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.02, leading to a 3.63% increase in the share price on the subsequent day.
Here's a look at Blade Air Mobility's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.10</td>
<td>-0.05</td>
<td>-0.06</td>
<td>-0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.12</td>
<td>-0.03</td>
<td>-0.15</td>
<td>-0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>5.0%</td>
<td>17.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746813835_0.png" alt="eps graph" />
<h3>Blade Air Mobility Share Price Analysis</h3>
Shares of Blade Air Mobility were trading at $2.96 as of May 08. Over the last 52-week period, shares are down 13.2%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Perspectives on Blade Air Mobility</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Blade Air Mobility.
The consensus rating for Blade Air Mobility is Buy, derived from 1 analyst ratings. An average one-year price target of $6.5 implies a potential 119.59% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Sun Country Airlines, Frontier Group Holdings and Allegiant Travel, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Sun Country Airlines, with an average 1-year price target of $15.25, suggesting a potential 415.2% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Frontier Group Holdings, with an average 1-year price target of $7.02, suggesting a potential 137.16% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Allegiant Travel, with an average 1-year price target of $61.0, suggesting a potential 1960.81% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for Sun Country Airlines, Frontier Group Holdings and Allegiant Travel, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blade Air Mobility</td>
<td>Buy</td>
<td>14.49%</td>
<td>$12.59M</td>
<td>-4.30%</td>
</tr>
<tr>
<td>Sun Country Airlines</td>
<td>Neutral</td>
<td>4.87%</td>
<td>$97.28M</td>
<td>6.23%</td>
</tr>
<tr>
<td>Frontier Group Holdings</td>
<td>Neutral</td>
<td>5.43%</td>
<td>$13M</td>
<td>-7.33%</td>
</tr>
<tr>
<td>Allegiant Travel</td>
<td>Neutral</td>
<td>11.37%</td>
<td>$115.95M</td>
<td>2.84%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Blade Air Mobility ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. However, it ranks at the top for Return on Equity.
<h3>Unveiling the Story Behind Blade Air Mobility</h3>
Blade Air Mobility Inc is a technology-powered air mobility platform that provides air transportation and logistics for hospitals and is a transporter of human organs for transplant, and for passengers, with helicopter and fixed-wing services predominantly in the Northeast United States, Southern Europe and Western Canada. The company's operating segments are; Passenger, and Medical. Majority of the revenue for the company is generated from its Medical segment which predominantly consists of transportation of human organs for transplant and the medical teams supporting these services. It also offers additional services including donor logistics coordination and support in evaluating potential donor organs. A substantial portion of the company's revenue is generated from the United States.
<h3>Blade Air Mobility's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Blade Air Mobility's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 14.49%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Blade Air Mobility's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -18.02% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Blade Air Mobility's ROE excels beyond industry benchmarks, reaching -4.3%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Blade Air Mobility's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -3.63%, the company showcases efficient use of assets and strong financial health.
Debt Management: Blade Air Mobility's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/BLDE/earnings">To track all earnings releases for Blade Air Mobility visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLDE

Earnings Outlook For Blade Air Mobility

Goldman Sachs analyst Gabriela Borges maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and lowers the price target from $900 to $795.

HUBS

Goldman Sachs Maintains Buy on HubSpot, Lowers Price Target to $795

Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Plug Power to report an earnings per share (EPS) of $-0.19.
Investors in Plug Power are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $1.42, leading to a 4.32% increase in the share price on the subsequent day.
Here's a look at Plug Power's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.23</td>
<td>-0.24</td>
<td>-0.32</td>
<td>-0.33</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.65</td>
<td>-0.25</td>
<td>-0.36</td>
<td>-0.43</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>3.0%</td>
<td>-5.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746813773_0.png" alt="eps graph" />
<h3>Market Performance of Plug Power's Stock</h3>
Shares of Plug Power were trading at $0.8504 as of May 08. Over the last 52-week period, shares are down 70.37%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Take on Plug Power</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Plug Power.
A total of 13 analyst ratings have been received for Plug Power, with the consensus rating being Neutral. The average one-year price target stands at $1.88, suggesting a potential 121.07% upside.
<h3>Peer Ratings Comparison</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Shoals Technologies Gr, Fluence Energy and Enovix, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Shoals Technologies Gr, with an average 1-year price target of $5.82, suggesting a potential 584.38% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Fluence Energy, with an average 1-year price target of $8.23, suggesting a potential 867.78% upside.</li>
<li>Analysts currently favor an Buy trajectory for Enovix, with an average 1-year price target of $14.43, suggesting a potential 1596.85% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for Shoals Technologies Gr, Fluence Energy and Enovix, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plug Power</td>
<td>Neutral</td>
<td>-13.81%</td>
<td>$-234.53M</td>
<td>-56.07%</td>
</tr>
<tr>
<td>Shoals Technologies Gr</td>
<td>Buy</td>
<td>-11.50%</td>
<td>$28.14M</td>
<td>-0.05%</td>
</tr>
<tr>
<td>Fluence Energy</td>
<td>Neutral</td>
<td>131.07%</td>
<td>$21.20M</td>
<td>-7.78%</td>
</tr>
<tr>
<td>Enovix</td>
<td>Buy</td>
<td>-3.30%</td>
<td>$261K</td>
<td>-9.76%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Plug Power is positioned at the bottom for Revenue Growth and Gross Profit among its peers. It is also at the bottom for Return on Equity.
<h3>About Plug Power</h3>
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
<h3>Financial Insights: Plug Power</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Plug Power's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -13.81% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -697.46%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -56.07%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Plug Power's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -32.07%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Plug Power's debt-to-equity ratio is below the industry average. With a ratio of 0.62, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/PLUG/earnings">To track all earnings releases for Plug Power visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PLUG

An Overview of Plug Power's Earnings

Goldman Sachs analyst Eric Sheridan maintains GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) with a Neutral and lowers the price target from $6 to $5.

GDRX

Goldman Sachs Maintains Neutral on GoodRx Holdings, Lowers Price Target to $5

Goldman Sachs analyst Brian Lee maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Buy and lowers the price target from $9 to $8.

FLNC

Goldman Sachs Maintains Buy on Fluence Energy, Lowers Price Target to $8

In the last three months, 8 analysts have published ratings on Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $13.88, a high estimate of $18.00, and a low estimate of $12.00. Marking an increase of 6.28%, the current average surpasses the previous average price target of $13.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1746813677_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Rocket Companies among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Bose George</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Terry Ma</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Bose George</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Bose George</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Underperform</td>
<td>$12.00</td>
<td>$10.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rocket Companies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Rocket Companies compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Rocket Companies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Rocket Companies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RKT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rocket Companies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Rocket Companies's Background</h2>
Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and will also be the largest mortgage servicer in the US following its acquisition of the Mr. Cooper Group.
<h3>Rocket Companies: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Rocket Companies displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 161.83%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Rocket Companies's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 1.97%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Rocket Companies's ROE stands out, surpassing industry averages. With an impressive ROE of 5.0%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Rocket Companies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.14%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Rocket Companies's debt-to-equity ratio stands notably higher than the industry average, reaching 7.6. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Rocket Companies Stock

WIIM

DAVE

Dave shares are trading higher after the company reported strong Q1 results and raised its FY25 sales guidance.

In the latest quarter, 4 analysts provided ratings for NCR Voyix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VYX#NYSE">VYX</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $14.0, a high estimate of $17.00, and a low estimate of $11.00. Highlighting a 13.85% decrease, the current average has fallen from the previous average price target of $16.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1746813664_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of NCR Voyix's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to NCR Voyix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NCR Voyix compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of NCR Voyix's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into NCR Voyix's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VYX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NCR Voyix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind NCR Voyix</h2>
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.
<h3>A Deep Dive into NCR Voyix's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3M period, NCR Voyix faced challenges, resulting in a decline of approximately -14.32% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: NCR Voyix's net margin excels beyond industry benchmarks, reaching -2.05%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): NCR Voyix's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.44% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): NCR Voyix's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.31%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.44, NCR Voyix faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying NCR Voyix: Insights From 4 Analyst Reviews

Ratings for Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $5.82, with a high estimate of $7.00 and a low estimate of $3.40. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.2%. 
<img src="https://www.benzinga.com/files/images/story/2025/1746813656_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Shoals Technologies Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.50</td>
<td>$4.50</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$3.40</td>
<td>$4.60</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Christopher Dendrinos</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.50</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Shoals Technologies Gr. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Shoals Technologies Gr compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Shoals Technologies Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Shoals Technologies Gr's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SHLS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Shoals Technologies Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Shoals Technologies Gr Better</h2>
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
<h3>Unraveling the Financial Story of Shoals Technologies Gr</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Shoals Technologies Gr faced challenges, resulting in a decline of approximately -11.5% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Shoals Technologies Gr's net margin excels beyond industry benchmarks, reaching -0.35%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Shoals Technologies Gr's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.05% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.04%, the company showcases effective utilization of assets.
Debt Management: Shoals Technologies Gr's debt-to-equity ratio is below the industry average. With a ratio of 0.25, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SHLS

What Analysts Are Saying About Shoals Technologies Gr Stock

Ouster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.42, a high estimate of $17.00, and a low estimate of $11.00. This current average reflects an increase of 6.81% from the previous average price target of $13.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1746813648_0_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Ouster. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$13.68</td>
<td>-</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Kevin Garrigan</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ouster. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ouster compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Ouster's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OUST/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ouster analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Ouster Better</h2>
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
<h3>Financial Milestones: Ouster's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Ouster's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 23.11%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ouster's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -78.88%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Ouster's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -13.46%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Ouster's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -8.93%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Ouster's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Amer Sports

Interés en corto

Amer Sports (NYSE:AS) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL